U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Eprinomectin is a mixture of two homologues, eprinomectin B1a (90%) and eprinomectin B1b (10%). The drug is indicated for the treatment of gastrointestinal roundworms in cattle. Eprinomectin acts by binding to glutamate-gated chloride ion channels that leads to paralysis and death of the parasite.

CNS Activity

CNS Non-penetrant
1,014

Originator

Merck
216

Approval Year

1997
172

Targets

Primary TargetPharmacologyConditionPotency
Glutamate-gated chloride channel
3
Binding Agent
1,064

Conditions

ConditionModalityTargetsHighest PhaseProduct
Gastrointestinal roundworms infection
2
 Curative
Approved
8,429
EPRINEX

PubMed

Patents

US20110281920 A1
1
WO2012001083 A2
1
WO2014098623 A1
1

Sample Use Guides

In Vivo Use Guide
One milliliter (5 milligrams per 10 kilograms of body weight (500 microgram per kilogram).
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Mixture
Record UNII
75KP30FD8O
Record Status Validated (UNII)
Record Version
All of the following components must be present:
Structure of EPRINOMECTIN B1B
Structure of EPRINOMECTIN B1A
Definition References
(3)
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966